U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.
Shares of Silence Therapeutics PLC – ADR (NASDAQ:SLN) rose sharply after the company agreed to be acquired by Merck KGaA, Darmstadt, Germany.
The purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of around $1.3 billion.
Silence Therapeutics shares jumped 125.7% to $19.60 on Monday.
Here are some other big stocks recording gains in today’s session.
- Disc Medicine Inc (NASDAQ:IRON) gained 24.7% to $70.90 after the company announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria, including X-linked protoporphyria met all its primary and secondary endpoints.
- Applied Digital Corp (NASDAQ:APLD) surged 9.6% to $19.78.
- AXT Inc (NASDAQ:AXTI) rose 9.4% to $56.33.
- Parabilis Medicines Inc (NASDAQ:PBLS) gained 9.3% to $24.86. Parabilis Medicines will present updated clinical data for Zolucatetide in patients with desmoid tumors at ESMO Congress 2026.
- United States Antimony Corp (NYSE:UAMY) rose 9.1% to $3.10.
- SanDisk Corp (NASDAQ:SNDK) rose 7.8% to $1,401.54.
- Maxlinear Inc (NASDAQ:MXL) gained 7.7% to $76.82.
- FormFactor Inc (NASDAQ:FORM) rose 6.6% to $111.91.
- Western Digital Corp (NASDAQ:WDC) climbed 5.9% to $351.60.
- Veradermics Inc (NYSE:MANE) gained 5.7% to $115.00 as the company’s oral VDPHL01 achieved early, consistent, and robust hair growth in positive Phase 3 ‘304’ clinical trial in male pattern hair loss.
- AST SpaceMobile Inc (NASDAQ:ASTS) rose 5.5% to $42.88.
- Intel Corp (NASDAQ:INTC) gained 4.8% to $94.23. JP Morgan analyst Harlan Sur upgraded Intel from Underweight to Neutral and maintained the price target of $85.
- Rambus Inc (NASDAQ:RMBS) rose 4.7% to $91.35.
- Alpha and Omega Semiconductor Ltd (NASDAQ:AOSL) climbed 4.4% to $22.70. Alpha and Omega Semiconductor will announce fiscal first quarter financial results on Nov. 5.
- Aehr Test Systems (NASDAQ:AEHR) gained 4.2% to $63.16.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.

